37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue (excluding COVID-19 tests) compared to the same period last year Reiterating full year 2022 total revenue guidance of $215-225 million Sema4 to host conference call today at 4:30 p.m. ET STAMFORD, Conn., March 14, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), an AI-driven genomic and clinical data intelligence platform company, today reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on key strategic and ope

Sema4 Holdings Corp ("Sema4") to debut on Nasdaq as a publicly traded company dedicated to transforming healthcare by applying artificial intelligence and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human healthBusiness combination expected to result in ~$500 million in cash proceeds to Sema4 to accelerate organic and inorganic growthCombined company to trade on Nasdaq under ticker "SMFR" STAMFORD, Conn., July 22, 2021 (GLOBE NEWSWIRE) -- Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the completion of its business combination with CM Life

Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the appointment of renowned executive Jason Ryan to its Board of Directors. Mr. Ryan will begin serving on Sema4's Board of Directors upon his official appointment after Sema4 closes its previously announced business combination with CM Life Sciences (NASDAQ:CMLF), a special purpose acquisition company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210707005228/en/Jason Ryan (Photo: Business Wire) Mr. Ryan most recently served as Chief Operating and Financial Officer of Magenta Therapeutics (NA

CM Life Sciences (NASDAQ:CMLF), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, has filed its definitive proxy statement with the Securities and Exchange Commission (the "SEC") in connection with the previously announced proposed business combination with Sema4. The definitive proxy statement contains important information about the proposed business combination contemplated by the Agreement and Plan of Merger dated February 9, 2021, by and between CM Life Sciences and Sema4. A special meeting of CM Life Sciences' stockholders to approve the business combination will be held virtually on July 21, 2021 at 10:00 a.m. E

Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the appointment of Andrew Kasarskis, PhD, to the newly established role of Chief Data Officer (CDO). Dr. Kasarskis brings more than 20 years of leadership and broad experience in industry and academia that includes a strong focus on digital analytics and genomics and internationally recognized research in the life sciences. At Sema4, he will be responsible for establishing additional structures and processes to further optimize the company's health intelligence platform and orchestrating data use and data science to support research, development, and innov

STAMFORD, Conn.--(BUSINESS WIRE)--Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, and CM Life Sciences (Nasdaq: CMLF), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced the filing of an amended preliminary proxy statement related to their proposed business combination. The filing of the amended proxy statement marks the next step in the formal Securities and Exchange Commission (SEC) review process required to finalize the definitive proxy statement that will be sent to CM Life Sciences shareholders. “Filing our updated p

Expanding their investment in precision medicine, AdventHealth is leveraging Sema4's health intelligence platform to enable a range of clinical and research initiatives AdventHealth and Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced a wide-ranging collaboration that builds upon the current AdventHealth Genomics and Personalized Health Program to provide new research insights and to prevent, detect and treat disease in their patients. Initially, AdventHealth and Sema4 will focus on accelerating research in AdventHealth's Orlando-area network, which includes more than 20 hospitals and emergency departm

Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced that members of the Sema4 management team will participate in fireside chats at two upcoming virtual investor conferences. Eric Schadt, PhD, Founder and Chief Executive Officer, and Isaac Ro, Chief Financial Officer, will present at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 and the Goldman Sachs Annual Global Healthcare Conference on Tuesday, June 8, 2021. Event: Jefferies Virtual Healthcare Conference Date: Friday, June 4, 2021 Time: 11:00 a.m. ET / 8:00 a.m. PT Event: Goldman Sachs Annual Global Healthcare Conference Date: Tue

Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, and CM Life Sciences (NASDAQ:CMLF), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced the filing of the preliminary proxy statement related to their proposed business combination. The filing of the preliminary proxy statement initiates the formal Securities and Exchange Commission (SEC) review process required to finalize the definitive proxy statement that will be sent to CM Life Sciences shareholders. "This is an important milestone and begins the process of transitioning Sema4 into

CM Life Sciences and merger partner Sema4 remain committed to closing transaction as soon as practicable and expect to file proxy statement in next several days CM Life Sciences, Inc. (NASDAQ:CMLF) today announced that it has filed with the Securities and Exchange Commission (SEC) an amended annual report on Form 10-K/A and a Form 8-K reporting the restatement of certain of its previously issued financial statements. The restatement was following a statement issued on April 12, 2021 by the Acting Director of the Division of Corporation Finance and the Acting Chief Accountant of the SEC relating to reporting considerations for warrants issued by special purpose acquisition companies like C

SC 13D - Sema4 Holdings Corp. (0001818331) (Subject)

SC 13D - Sema4 Holdings Corp. (0001818331) (Subject)

SC 13D - Sema4 Holdings Corp. (0001818331) (Subject)

SC 13G - Sema4 Holdings Corp. (0001818331) (Subject)

SC 13G - CM Life Sciences, Inc. (0001818331) (Subject)

SC 13G - CM Life Sciences, Inc. (0001818331) (Subject)